Siliq · DIN 02473623 · 210 mg/1.5 mL · injection, pre-filled syringe
Limited Use, Reason for Use code 553 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 553 required
Write on scriptReason for Use code 553 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 553
Reason for Use code 553
For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below).
Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued.
Approvals will only allow for standard dosing for Siliq 210mg subcutaneously at weeks 0, 1 and 2, and then every 2 weeks. If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended and the physician should consider switching to an alternative biologic agent.
Note 1: Definition of severe plaque psoriasis:
- Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND
- Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND
- Dermatology Life Quality Index (DLQI) score of at least 10.
Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies:
- 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND
- 12 week trial of phototherapy (unless not accessible), AND
- 6 month trial of at least 2 systemic, oral agents used alone or in combination
- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine
Maintenance/Renewal:
After 3 months of therapy, patients who respond to therapy should have:
- at least 50% reduction in PASI, AND
- at least 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Siliq · DIN 02473623
Manufacturer: Valeant Canada Ltd.; listing date 2019-04-30
Health Canada: Marketed since 2019-06-07 · brand SILIQ · ATC L04AC12 BRODALUMAB · form Solution · route Subcutaneous · ingredients BRODALUMAB 210 MG/1.5ML · company Bausch health, canada inc. · schedule Prescription, Schedule d
Siliq: Formulary list price $645.00 per unit (the source does not state the unit; exact figure $645.0000). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02473623)
Source record
DIN 02473623: Siliq
Raw flags: sec12=Y, sec3=Y
Item: 843600104; group id 858; item number 2079; lccId 00316; manufacturer id VAL
Source form: Inj Sol-Pref Syr; strength: 210mg/1.5mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $645.0000; ministry $645.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02473623
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96302
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02473623
Shortage record checked October 6, 2026